WEDNESDAY, Feb. 23, 2022 (HealthDay Information) — Two doses of a brand new COVID-19 vaccine from Sanofi and GSK have been 100% efficient towards extreme illness and hospitalizations, the businesses introduced Wednesday.
The vaccine was additionally 75% efficient towards moderate-to-severe illness and 58% efficient towards symptomatic illness in a Part 3 medical trial.
And when used as a booster dose after one of many different out there COVID-19 vaccines, the brand new vaccine triggered an 18- to 30-fold improve in antibody ranges, the businesses stated in a assertion.
“We’re very happy with these knowledge, which affirm our robust science and the advantages of our COVID-19 vaccine, stated Thomas Triomphe, govt vp of Sanofi Vaccines.
“The Sanofi-GSK vaccine demonstrates a common potential to spice up all platforms and throughout all ages,” he stated within the assertion. “We additionally noticed sturdy efficacy of the vaccine as a major sequence in in the present day’s difficult epidemiological atmosphere. No different international Part 3 efficacy research has been undertaken throughout this era with so many variants of concern, together with Omicron, and these efficacy knowledge are much like the latest medical knowledge from licensed vaccines.”
Individuals are additionally studying…
In laboratory research, two doses of the Sanofi-GSK vaccine stimulated the manufacturing of extra neutralizing antibodies than an permitted mRNA vaccine, the businesses famous.
The info haven’t but been revealed.
The vaccine was protected and well-tolerated by adults of all ages, in response to the businesses. They stated they plan to submit the vaccine for emergency authorization to regulatory authorities in the US and Europe.
The Sanofi-GSK vaccine makes use of a barely modified model of the protein itself to stimulate an immune response, a generally used technique of creating vaccines.
It was certainly one of 4 candidates that obtained billions of {dollars} for growth from Operation Warp Pace, the Trump administration’s program to speed up vaccines. The businesses have been anticipated to hunt authorization for his or her vaccine final yr, however medical trials confirmed disappointing ends in older adults. So the businesses then developed a stronger model of the vaccine and examined it in new trials, the New York Occasions reported.
Final month, Novovax utilized to the U.S. Meals and Drug Administration for emergency authorization of the same protein-based COVID-19 vaccine.
Protein vaccines are comparatively cheap and should not require the ultra-cold storage wanted for mRNA vaccines, which can make protein-based vaccines extra doubtless for use in Africa, the place there are low vaccination charges, the Occasions reported.
Go to the U.S. Facilities for Illness Management and Prevention for extra on COVID vaccines.
SOURCES: Sanofi/GSK, information launch, Feb. 23, 2022; Novovax, information launch, Jan. 31, 2022; New York Occasions
This text initially ran on shopper.healthday.com.